What should I do if I become drug-resistant after taking Talazoparib?

If patients develop resistance to talazoparib after taking talazoparib (Talazoparib), they should communicate with their attending doctors in a timely manner and inform them of their resistance to talazoparib. They may use genetic testing, tumor tissue analysis and other methods to understand the resistance mechanism of talazoparib, and then be able to assess their condition and provide them with personalized treatment recommendations.

Normally, doctors will recommend trying other treatment options based on the patient's resistance mechanism and disease characteristics, which may include the use of otherPARP inhibitors, chemotherapy drugs, immunotherapy or other molecularly targeted drugs. Based on the latest clinical research and guidelines, a suitable treatment plan will be developed for the patient. In some cases, participating in relevant clinical trials may be a way to gain access to new treatment options. Clinical trials often involve new drugs or new treatment strategies that may have a positive impact on drug resistance in patients. Sometimes, a combination treatment regimen may be a better option, which means using several different treatments at the same time, such as chemotherapy, radiation, surgery, and targeted therapy, to maximize suppression of tumor growth and prolong survival.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).